Charles Makin is the Global Head of Real-World Evidence Strategy at Biogen (MA, USA).
In Makin’s current position, he oversees real-world evidence projects across all therapeutic areas for marketed and pipeline products.
Before joining Biogen, Makin served as the Vice President for ICON Plc.’s (Dublin, Ireland) Real-World Evidence Late Phase Research Unit, the world’s second largest research group dedicated to prospective data collection.
Prior to that, Makin held real-world evidence and health economics and outcomes research leadership positions at IQVIA (NC, USA), Optum (MN, USA), Anthem (IN, USA) and Humana (KY, USA).
Makin has served as the Principal Investigator on over 100 retrospective database analyses, global registries, medical chart reviews, economic models, patient-reported outcome studies and physician surveys across every major therapeutic area.
Makin holds a Bachelor of Science in Pharmacy, graduate degrees in Pharmacy, General Management and Marketing, and has a Fellowship in Pharmacoeconomics and Outcomes Research.